A first approval for a specific disease form
The Food and Drug Administration has expanded the approved use of Anktiva with Bacillus Calmette-Guérin, or BCG, to adults with high-grade papillary-only bladder cancer that has not invaded the bladder muscle and has not responded to BCG. The agency says it is the first treatment approved specifically for that patient group.
Anktiva, whose generic name is nogapendekin alfa inbakicept-pmln, was already approved with BCG for another form of high-risk non-muscle invasive bladder cancer involving carcinoma in situ. The October 14 decision extends that indication to papillary-only tumors.
Understanding the disease category
Non-muscle invasive bladder cancer remains in the bladder’s inner layers rather than growing into its muscle. Carcinoma in situ forms flat abnormal areas along the lining, while papillary tumors grow outward in finger-like projections. High-grade disease is more likely than low-grade disease to return or progress.
BCG is placed directly into the bladder to stimulate an immune response against cancer. Some tumors persist or come back despite that treatment. For those patients, decisions can involve additional local therapy, clinical trials or surgery, depending on disease features and overall health.
How the FDA used existing evidence
The earlier Anktiva approval was supported by a single-arm trial of 77 adults with BCG-unresponsive carcinoma in situ, with or without papillary tumors. Sixty-two percent achieved a complete response in follow-up assessments. Among responders, 58 percent maintained the response for at least twelve months and 40 percent for at least twenty-four months.
For the expanded indication, the FDA considered those results along with clinical and laboratory evidence that carcinoma in situ and high-grade papillary tumors often coexist, can be difficult to distinguish and carry overlapping risks. The agency concluded that evidence could support use in the papillary-only group.
This approach is not the same as a new randomized trial conducted only in papillary-only patients. The FDA is developing guidance on when scientific similarities can support this kind of evidence extension in BCG-unresponsive bladder cancer.
Treatment and safety considerations
Anktiva is administered with BCG through a catheter into the bladder once weekly for six weeks, with additional induction and maintenance treatment based on the response. Therapy can continue for as long as 37 months under the approved schedule.
Common adverse reactions and laboratory abnormalities include painful or frequent urination, urgency, blood in the urine, urinary tract infection, muscle or joint pain, chills, fever and increased creatinine or potassium. The prescribing information warns that delaying surgery to remove the bladder can allow cancer to spread and become fatal.
What the approval means for patients
The decision creates an additional approved option; it does not establish that Anktiva is appropriate for every person with bladder cancer. Tumor grade, prior BCG exposure, pathology, recurrence timing, surgical fitness and patient preferences all affect treatment planning.
Patients should discuss the full label, potential benefits, monitoring and the consequences of delaying cystectomy with a urologic oncologist. The most important practical change is that clinicians now have an FDA-approved therapy specifically covering the high-grade papillary-only, BCG-unresponsive group, supported through the agency’s evidence-extension approach.
The reported response rates come from the earlier carcinoma-in-situ cohort and should not be interpreted as a personalized probability for every newly eligible patient. Outcomes can differ with tumor characteristics and prior care. Patients should ask which evidence applies directly to their disease, what follow-up testing is required and at what point the treatment plan would shift toward surgery or another option.
Sources: FDA approval announcement · FDA prescribing and efficacy summary. Reporting reviewed October 17, 2026.